ZeNix trial success announced
15 July 2021
The ZeNix trial tested the BPaL regimen against highly drug-resistant TB, with lower levels of Linezolid to reduce toxicity. This combination was still effective at curing TB and fewer side effects were reported.
The results of ZeNix, a TB Alliance-sponsored Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-resistant strains of tuberculosis (TB) with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.1 The results from the trial, which was led by TB Alliance, a non-profit TB drug developer, were announced ahead of an oral abstract presentation next week at the 11th IAS Conference on HIV Science.
The °×С½ãÂÛ̳ Centre for Clinical Microbiology (CCM) was the central laboratory / laboratory monitoring lead and MRC Clinical Trials Unit at °×С½ãÂÛ̳ was the statistical lead for this trial.
More information can be found .
1. Conradie F. (2021) July 21. High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid [Conference presentation]. IAS 2021, Berlin, Germany.
The image shows Dr Julio Ortiz Canseco working in one of the CCM's containment level 3 laboratories (all rights reserved).